Essential medicines for breast cancer in low and middle income countries

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Bazargani, Y T ^a   de Boer, A ^a   Schellens, J H M ^a,b   Leufkens, H G M ^a   Mantel Teeuwisse, Aukje K ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; VINBLASTINE; ESSENTIAL DRUG;

ADVANCED CANCER; AFRICA; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; EARLY CANCER; EUROPE; FEMALE; GENE OVEREXPRESSION; HER2 GENE; HUMAN; INCOME; INTERNATIONAL COOPERATION; LOW AND MIDDLE INCOME COUNTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; NATIONAL ESSENTIAL MEDICINE LIST; ONCOGENE; PRACTICE GUIDELINE; SOUTHEAST ASIA; SOUTHERN EUROPE; WESTERN HEMISPHERE; WORLD HEALTH ORGANIZATION; BREAST NEOPLASMS; DECISION MAKING; DEVELOPING COUNTRY; ECONOMICS; PATHOLOGY; POVERTY;

BREAST NEOPLASMS; DECISION MAKING; DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; FEMALE; HUMANS; POVERTY; TAMOXIFEN;

EID: 84939440631     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1583-4     Document Type: Article

References (44)

1. American Cancer Society. Global Cancer Facts & Figures. 2011; Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf . Accessed 12/20, 2012.
2. World Health Organization. Breast cancer: prevention and control. 2013; Available at: http://www.who.int/cancer/detection/breastcancer/en/index1.html . Accessed 7/25, 2013.
3. World Health Organization. National cancer control programmes. 2013; Available at: http://www.who.int/cancer/nccp/en/ . Accessed 7/25, 2013.
4. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, et al. Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer. 2008;113(8 Suppl):2269-81.
5. El Saghir NS, Adebamowo CA, Anderson BO, Carlson RW, Bird PA, Corbex M, et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast. 2011;20 Suppl 2:S3-S11.
6. Anderson BO, Cazap E, El Saghir NS, Yip CH, Khaled HM, Otero IV, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol. 2011;12(4):387-98.
7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47.
8. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242-52.
9. Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J. 2006;12 Suppl 1:S3-S15.
10. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN, et al. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer. 2008;113(8 Suppl):2315-24.
11. Anderson BO, Cazap E. Breast health global initiative (BHGI) outline for program development in Latin America. Salud Publica Mex. 2009;51 Suppl 2:s309-15.
12. Yip CH, Cazap E, Anderson BO, Bright KL, Caleffi M, Cardoso F, et al. Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative. Breast. 2011;20 Suppl 2:S12-9.
13. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14(5):391-436.
14. van den Ham R, Bero L, Laing R. The World Medicines Situation 2011; selection of essential medicines. Available at: http://apps.who.int/medicinedocs/en/m/abstract/Js18770en/ . Accessed 12/4, 2012.
15. Bazargani YT, de Boer A, Schellens JH, Leufkens HG, Mantel-Teeuwisse AK. Selection of oncology medicines in low- and middle-income countries. Ann Oncol. 2014;25(1):270-6.
16. World health Organization. Essential Medicines Lists and Formularies. Available at: http://www.who.int/selection_medicines/country_lists/en/index.html . Accessed 11/23, 2012.
17. Wang L, Ma E, Xu W. Comparative Analysis of China National & Twenty-two Selected Provincial Essential Medicine Lists to the WHO 2011 Model List. Available at: http://apps.who.int/medicinedocs/en/m/abstract/Js18851en/ . Accessed 11/23, 2012.
18. Sheri A, Johnston S. New developments and future directions in systemic therapy. Clin Oncol (R Coll Radiol). 2013;25(2):117-26.
19. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
20. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-83.
21. Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS, et al. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1077-85.
22. World health Organization. WHO geographic regions. Available at: http://www.who.int/about/regions/en/index.html . Accessed 11/23, 2012.
23. The World Bank. World Bank classification of countries. Available at: http://data.worldbank.org/indicator/NY.GNP.PCAP.CD . Accessed 11/23, 2012.
24. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33(5):315-8.
25. Brower V. Developing nations face challenges as breast cancer rises. J Natl Cancer Inst. 2011;103(24):1812-4.
26. The World Bank. Health expenditure per capita (current US$). 2014; Available at: http://data.worldbank.org/indicator/SH.XPD.PCAP/countries/XM?display=graph . Accessed 02/11, 2014.
27. Chavarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A, Finkelstein DM, et al. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 2012;13(8):e335-43.
28. Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012;13(3):e95-e102.
29. Griffin S, Dunn G, Palmer S, Macfarlane K, Brent S, Dyker A, et al. The use of paclitaxel in the management of early stage breast cancer. Health Technol Assess. 2009;13 Suppl 1:15-22.
30. Chilcott J, Lloyd Jones M, Wilkinson A. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal. Health Technol Assess. 2009;13 Suppl 1:7-13.
31. Lopes GL. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol. 2013;24 Suppl 5:v13-6.
32. Management Sciences for Health. International Drug Price Indicator Guide. 2012; Available at: http://erc.msh.org/dmpguide/index.cfm?search_cat=yes&display=yes&module=dmp . Accessed 1/12, 2014.
33. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008;8(4):324-33.
34. Parkinson B, Pearson SA, Viney R. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Econ. 2013;14:363.
35. When the price is right. Nat Biotechnol. 2006;24(5):473.
36. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 2012;26(3):447-81. vii.
37. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1):1-16.
38. Vargas-Rivas JE, Montes-Casas MM, Cancela-Diez B, Martinez-Martinez F, Sabater-Hernandez D, Calleja-Hernandez MA. Study of compliance with prescription information sheet of trastuzumab prescriptions in a tertiary level hospital. Farm Hosp. 2012;36(3):135-40.
39. US$54 billion worth of biosimilar patentsexpiring before 2020. 2011; Available at: http://www.gabionline.net/Biosimilars/Research/US-54-billion-worth-of-biosimilar-patents-expiring-before-2020 . Accessed 03/28, 2013.
40. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.
41. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
42. Gyorki DE, Muyco A, Kushner AL, Brennan MF, Kingham TP. Cancer surgery in low-income countries: an unmet need. Arch Surg. 2012;147(12):1135-40.
43. Eng A, McCormack V, dos-Santos-Silva I. Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med. 2014;11(9):e1001720.
44. Bazargani YT, Ewen M, de Boer A, Leufkens HGM, Mantel-Teeuwisse AK. Essential medicines are more available than other medicines around the globe. PLoS One. 2014;9(2):e87576.